Genprex, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Genprex, Inc. (GNPX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $60.45 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Genprex, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $60.45K, a 31.87% decline year-over-year.
- Genprex, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $64.45K, a 64.13% decline year-over-year.
- Genprex, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $18.22K, a 95.56% decline year-over-year.
- Genprex, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $88.73K, a 95.67% decline year-over-year.
- Genprex, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $304.89K, a 90.15% decline from fiscal 2024.
- Genprex, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.10M, a 42.56% decline from fiscal 2023.
- Genprex, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $5.39M, a 17.97% increase from fiscal 2022.
- Genprex, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.57M, a 12.00% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $60.45K 10-Q · filed 2026-08-14 | $124.90K derived: sum of 2 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $64.45K 10-Q · filed 2026-08-14 | |||||
| 2025-12-31 | $304.89K 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | $18.22K 10-Q · filed 2025-11-14 | $106.95K derived: sum of 2 quarters · filed 2026-08-14 | $286.63K derived: sum of 3 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $88.73K 10-Q · filed 2026-08-14 | $88.80K 10-Q · filed 2025-08-14 | $268.42K derived: sum of 2 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $179.68K 10-Q · filed 2026-08-14 | $179.69K 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | $3.10M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $410.58K 10-Q · filed 2025-11-14 | $2.46M derived: sum of 2 quarters · filed 2025-11-14 | $2.79M derived: sum of 3 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $2.05M 10-Q · filed 2025-11-14 | $2.05M 10-Q · filed 2024-08-09 | $2.38M derived: sum of 2 quarters · filed 2025-11-14 | |||
| 2024-03-31 | $335.25K 10-Q · filed 2025-11-14 | |||||
| 2023-12-31 | $5.39M 10-K · filed 2025-04-01 | |||||
| 2023-09-30 | $1.49M 10-Q · filed 2024-11-13 | $3.03M derived: sum of 2 quarters · filed 2024-11-13 | $4.34M derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $1.54M 10-Q · filed 2024-11-13 | $2.85M derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | $1.31M 10-Q · filed 2024-11-13 | $1.32M 10-Q · filed 2023-05-22 | ||||
| 2022-12-31 | $4.57M 10-K · filed 2024-04-01 | |||||
| 2022-09-30 | $1.21M 10-Q · filed 2023-11-14 | $1.15M 10-Q · filed 2022-11-14 | $2.34M derived: sum of 2 quarters · filed 2023-11-14 | $3.38M derived: sum of 3 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $1.13M 10-Q · filed 2023-11-14 | $538.03K 10-Q · filed 2022-08-12 | $2.17M derived: sum of 2 quarters · filed 2023-11-14 | |||
| 2022-03-31 | $1.04M 10-Q · filed 2023-11-14 | $1.45M 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $5.19M 10-K · filed 2023-03-31 | $4.12M 10-K · filed 2022-03-30 | ||||
| 2021-09-30 | $658.58K 10-Q · filed 2022-11-14 | $1.77M derived: sum of 2 quarters · filed 2022-11-14 | $2.43M derived: sum of 3 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $1.12M 10-Q · filed 2022-11-14 | $1.12M 10-Q · filed 2021-08-13 | $1.77M derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-03-31 | $651.09K 10-Q · filed 2022-11-14 | |||||
| 2020-12-31 | $4.09M 10-K · filed 2022-03-30 | |||||
| 2020-09-30 | $432.59K 10-Q · filed 2021-11-15 | $2.79M derived: sum of 2 quarters · filed 2021-11-15 | $3.54M derived: sum of 3 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $2.36M 10-Q · filed 2021-11-15 | $3.11M derived: sum of 2 quarters · filed 2021-11-15 | ||||
| 2020-03-31 | $752.44K 10-Q · filed 2021-11-15 | |||||
| 2019-12-31 | $3.06M 10-K · filed 2021-03-26 | |||||
| 2019-09-30 | $540.81K 10-Q · filed 2020-11-12 | $2.16M derived: sum of 2 quarters · filed 2020-11-12 | $2.49M derived: sum of 3 quarters · filed 2020-11-12 | |||
| 2019-06-30 | $1.62M 10-Q · filed 2020-11-12 | $1.95M derived: sum of 2 quarters · filed 2020-11-12 | ||||
| 2019-03-31 | $330.63K 10-Q · filed 2020-11-12 | $522.70K 10-Q/A · filed 2019-05-20 | ||||
| 2018-12-31 | $4.88M 10-K · filed 2020-03-30 | |||||
| 2018-09-30 | $79.65K 10-Q · filed 2019-11-14 | $3.21M derived: sum of 2 quarters · filed 2019-11-14 | $3.25M derived: sum of 3 quarters · filed 2019-11-14 | |||
| 2018-06-30 | $3.13M 10-Q · filed 2019-11-14 | $3.17M derived: sum of 2 quarters · filed 2019-11-14 | ||||
| 2018-03-31 | $46.86K 10-Q · filed 2019-11-14 | $223.48K 10-Q/A · filed 2019-05-20 | ||||
| 2017-12-31 | $228.66K 10-K · filed 2019-04-01 | |||||
| 2016-12-31 | $2.24M 10-K · filed 2018-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |